The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of amrubicin plus erlotinib in previously treated, advanced non-small cell lung cancer with wild-type EGFR (TORG1320).
 
Shinobu Hosokawa
Honoraria - AstraZeneca Japan; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical
 
Akihiro Bessho
Honoraria - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Amgen; AstraZeneca; Bayer Yakuhin; Kyorin; Ono Pharmaceutical; Pfizer; Taisho Toyama Pharma
 
Sakiko Otani
No Relationships to Disclose
 
Jiichiro Sasaki
Honoraria - Chugai Pharma
Research Funding - Chugai Pharma
 
Satoshi Igawa
No Relationships to Disclose
 
Yoshiro Nakahara
Honoraria - AstraZeneca Japan; Chugai Pharma; Kyowa Hakko Kirin; Lilly; Nippon Boehringer Ingelheim; Taiho Pharmaceutical
Consulting or Advisory Role - Meiji Seika Kaisha
Research Funding - SRL Diagnostics
 
Nobuaki Fukamatsu
No Relationships to Disclose
 
Takashi Kasai
No Relationships to Disclose
 
Tomohide Sugiyama
No Relationships to Disclose
 
Nobuhiko Seki
Consulting or Advisory Role - AstraZeneca Japan; Daiichi Sankyo; Lilly Japan; MSD Oncology
Speakers' Bureau - AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Boehringer Ingelheim
 
Yukiko Nakamura
No Relationships to Disclose
 
Takaaki Tokito
No Relationships to Disclose
 
Noriyuki Masuda
Honoraria - Chugai Pharma; Nippon Kayaku
 
Koshiro Watanabe
No Relationships to Disclose